Mariner’s Arbutus Biopharma ABUS Stock Holding History

Mariner’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,997	Closed	-$25K	–	2737
2022 Q3	$25K	Buy	+12,997	New	+$30.6K	﹤0.01%	2371

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mariner's ABUS Position: Q4 2022 in Review

Mariner sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 12,997 shares — an estimated $25K sold.

Mariner first reported a position in ABUS in Q3 2022 and held it in 1 quarter. The position peaked at $25K in Q3 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

Mariner reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
Mariner sold 12,997 Arbutus Biopharma shares in Q4 2022, an estimated $25K.
Mariner first reported a position in Arbutus Biopharma in Q3 2022 and held it in 1 quarter.
Mariner's Arbutus Biopharma position peaked at $25K in Q3 2022.
114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.